Abstract:BackgroundAn ageing population and lifestyle changes have led to increased cardiovascular disease-related morbidity and mortality in China, where an estimated 230 million people have cardiovascular disease. Long-term antiplatelet therapy with aspirin and clopidogrel are used for treatment and post-stenting primary prevention of acute coronary syndrome, but the risk of bleeding complications is high. This study aimed to identify the target of the newly developed antiplatelet agent ADTM, originating from traditional Chinese herbs. We also investigated the antiplatelet and cardioprotective effects of ADTM.MethodsWe developed ADTM by conjugating danshensu and tetramethylpyrazine, which are active compounds in the herbs danshen (Salvia miltiorrhizae) and chuanxiong (Ligustium wallichii Franch), respectively. To identify the target of ADTM, we incubated its biotinylated analogue with rat blood platelet lysates, then used chemical proteomics to precipitate protein complexes. We compared the antiplatelet effect of ADTM with clopidogrel in a rat model in vivo by administrating ADTM (5–20 mg/kg) and clopidogrel (18 mg/kg) intravenously daily for 5 days, and inducing platelet aggregation by adenosine diphosphate. We also assessed the inhibitory effects of ADTM and clopidogrel on ferric chloride (FeCl3)-induced venous thrombus formation. We further assessed the cardioprotective effects of ADTM in a canine coronary artery occlusion-reperfusion model. The left anterior descending coronary artery was occluded for 20 min followed by reperfusion in five beagles (weighing about 12 kg). 15 min after occlusion, ADTM (6mg/kg) or nitroglycerin (45 μg) was administered for 3 min continuously.FindingsResults of chemical proteomics showed that ADTM targets ERp57. The inhibitory effects of ADTM on platelet aggregation were similar to clopidogrel in the rat model (mean 40% [SD 11] for ADTM [p=0·018 vs control] and 38% [9] for clopidogrel [p=0·0073 vs control; p=0·78 vs ADTM). Similarly, the inhibitory effects on FeCl3-induced venous thrombus formation were 50% (SD 10) for ADTM (p=0·0087 vs vehicle control) and 42% (6) for clopidogrel (p=0·0093 vs vehicle control; p=0·85 vs ADTM). ADTM increased mean coronary blood flow by 36% (SD 15; p=0·0165 for before vs after ADTM administration) and decreased mean arterial pressure (MAP) from 102 mm Hg (2·7) to 96 mm Hg (1·3; p=0·0031). Coronary blood flow did not differ between before and after nitroglycerin administration (p=0·49), but nitroglycerin did decrease mean arterial pressure from 102 mm Hg (1·6) to 92 mm Hg (1·5; p=0·0076). ADTM and nitroglycerin reduced the infarct size of cardiac tissue by a mean of 10% (SD 3; p=0·0217) and 8% (2; p=0·0072), respectively.InterpretationADTM is a ligand that targets ERp57 and displays antiplatelet and cardioprotective effects in animal models. ADTM represents a potential lead compound for further investigation and development of new antiplatelet drugs with reduced bleeding risk.FundingThe National Natural Science Foundation of China (NSFC-81403139) and University of Macau (MYRG2015-00161-ICMS-QRCM).

Progress in Signaling Transduction During Platelet Activation and Antiplatelet Agents

Progress in Mechanism of the Active Components of Chinese Material Medical on Anti-platelet Aggregation

Multiobjective Optimization on Antiplatelet Effects of Three Components Combination by Quantitative Composition-Activity Relationship Modeling and Weighted-Sum Method

Review ontheEffect of Tea on PlateletActivation

Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic

Applications of platelets in studies on traditional Chinese medicines promoting blood circulation to remove blood stasis

Mechanism and Potential Target of Blood-Activating Chinese Botanical Drugs Combined With Anti-Platelet Drugs: Prevention and Treatment of Atherosclerotic Cardiovascular Diseases

Components of Traditional Chinese Medicine Inhibit Platelet Aggregation by Blocking ADP Receptor Subtypes P2Y1 and P2Y12

Developments in Inhibiting Platelet Aggregation Based on Different Design Strategies

The Progress in the Research of Antiplatelet Agents (1995–2017)

Progress in research of P2Y12 receptor antagonists antiplatelet drugs

Receptor-mediated Inhibitory Mechanisms and the Regulation of Platelet Function

The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: From molecular mechanisms to clinical applications

Development of the Novel Antiplatelet Agent ADTM, Originating from Traditional Chinese Medicine: a Chemical Proteomic Analysis and In-Vivo Assessment of Efficacy in an Animal Model

Effective components and mechanism analysis of anti-platelet aggregation effect of Justicia procumbens L.

Effect on Platelet Aggregation Activity: Extracts from 31 Traditional Chinese Medicines with the Property of Activating Blood and Resolving Stasis

Comparative Study on Effects of Active Ingredients of Several Traditional Chinese Medicines on Rabbit Platelet Aggregation in Vitro

Atractylodes Lactone Compounds Inhibit Platelet Activation

Progress in research of platelet integrin receptors and related drugs

Abstract 525: Integration of Platelet Agonist Signaling During the Hemostatic Response in vivo

Correlation between Platelet Gelsolin and Platelet Activation Level in Acute Myocardial Infarction Rats and Intervention Effect of Effective Components of Chuanxiong Rhizome and Red Peony Root